Home Magazines Editors-in-Chief FAQs Contact Us

Impressive clinical course of diabetic patient with various medical problems and remarkable improvement by insulin degludec and liraglutide (Xultophy)

MOJ Clinical & Medical Case Reports
Yoshikane Kato,1 Hiroshi Bando,1,2 Hisako Yamashita,1 Seigo Yada,1 Shunsuke Tokuhara,1 Hatsue Tokuhara,1 Teruo Mutsuda1

PDF Full Text


Diabetes mellitus causes macrovascular, microvascular angiopathy, and increased cancer risk. Authors et al. have continued clinical practice and research on diabetes cases. Current case is impressive 79-year-old female with various diseases. They include asthma and COPD, steroid intake for years, sleep apnea syndrome (SAS), Continuous Positive Airway Pressure (CPAP) therapy, tongue cancer, arteriosclerosis, bone complications, Carpal tunnel syndrome (CTS), and so on. When she developed hyperglycemia with 9.0% of HbA1c, Xultophy® was started. It contains insulin degludec and liraglutide which is Glucagon-like peptide-1 receptor agonist (GLP-1 RA). HbA1c values decreased as 7.9%, 7.3%, 6.9%, 6.5% in 1-4 months, with remarkable effect. The satisfactory efficacy may be from double agents of Xultophy® or probable secondary diabetes due to continuation of steroid of the case. This report will be expected to be some reference in the future diabetic research development.


Xultophy®, glucagon-like peptide-1 receptor agonist (GLP-1 RA), Japan LCD promotion association (JLCDPA), Carpal tunnel syndrome (CTS), oral hyperglycemic agents (OHAs)